JSC AVVA RUS

JSC AVVA RUS (АО «АВВА РУС») is a Russian pharmaceutical company headquartered in Kirov, Russia. It describes itself as one of the leading pharmaceutical enterprises in Russia, engaged in the development, production and sale of medicines. The company's stated mission is "Human microecology is our profession!" and its priority is the development of original drugs with a unique safety profile for patients. According to its official website, AVVA RUS has 30 years of successful work in the pharmaceutical market, more than 70 medicine positions, over 100 clinical studies, and more than 750 employees. The company's product portfolio focuses on gastroenterology and dermatology, with flagship brands including Lactofiltrum (a combination of lactulose and hydrolyzed lignin), Filtrum (hydrolyzed lignin), and Mikrazim (pancreatin) in 10,000 IU and 25,000 IU capsule forms. These products are positioned for intestinal disorders, detoxification, restoration of microflora, and digestive enzyme support. AVVA RUS operates a manufacturing site in Kirov at Luganskaya 53A. It has obtained Russian GMP certification (No. GMP-0055-000493/20) from the Ministry of Industry and Trade of the Russian Federation, as well as international GMP EU certificates (No. AVVA RUS19 2018/01 and No. AVVA RUS18 2018/01) issued by the Ministry of Health of the Republic of Cyprus. The company also provides contract development, contract manufacturing, and exclusive distribution and promotion services. Internationally, AVVA RUS has expanded its regulatory footprint: in 2018 it received the European GMP EU certificate and signed agreements in Mongolia for product supply; in 2020 it passed an audit by Saudi Arabian FDA bodies for GMP compliance; in 2023 it registered its Kirov production site in the United Arab Emirates, allowing supplies to the UAE market; and in 2025 its Kirov branch received GMP certification from the Republic of Cyprus. The company is included in the list of systemically important enterprises of the Kirov region. Its General Director is Alexey Glebovich Egorov.

JSC AVVA RUS (АО «АВВА РУС») is a Russian pharmaceutical company based in Kirov. Its official website states that the company has 30 years of successful work in the pharmaceutical market, which places its founding around the mid-1990s; the company page lists the General Director as Alexey Glebovich Egorov with a tenure noted as 1996–2026, indicating leadership continuity since 1996. The company describes itself as one of the leading pharmaceutical enterprises in Russia, engaged in the development, production and sale of medicines, with a mission centered on "human microecology." Over its history, AVVA RUS has built a portfolio of more than 70 medicines and conducted over 100 clinical studies. Its flagship products are in gastroenterology and dermatology: Lactofiltrum (a unique combination of sorbent and prebiotic, lactulose plus hydrolyzed lignin), Filtrum (hydrolyzed lignin), and Mikrazim (pancreatin) in 10,000 IU and 25,000 IU capsules. The company operates a manufacturing site at Luganskaya 53A in Kirov and provides contract development, contract manufacturing, and exclusive distribution and promotion services. A major theme of AVVA RUS's history is international quality certification and market expansion. In 2018, the company received the European GMP EU certificate and concluded agreements with a company in Mongolia for the supply of AVVA RUS products. In 2020, it successfully passed an audit by Saudi Arabian FDA bodies for compliance with GMP standards of that region. In 2023, AVVA RUS registered its production site at Luganskaya 53A in Kirov in the United Arab Emirates, giving it the right to supply medicines to the UAE market. In late 2023, the Kirov branch underwent an audit by structures for supervision and control of medicines of the Republic of Cyprus for GMP compliance, and in 2025 it received documentary confirmation of successful completion with a corresponding certificate. The company is included in the list of systemically important enterprises of the Kirov region. Domestically, AVVA RUS holds GMP certification from the Russian Ministry of Industry and Trade (No. GMP-0055-000493/20) and international GMP EU certificates from the Ministry of Health of the Republic of Cyprus (No. AVVA RUS19 2018/01 and No. AVVA RUS18 2018/01). Its pharmaceutical quality system covers the full lifecycle from pharmaceutical development to distribution. The company employs more than 750 people and continues to position itself as a developer and manufacturer of innovative medicines with improved safety profiles.

• 2025

  Kirov branch of JSC AVVA RUS receives GMP certification from the Republic of Cyprus after a successful audit.

• 2023

  AVVA RUS registers its production site at Kirov, Luganskaya 53A in the United Arab Emirates, allowing supplies to the UAE market.

• 2020

  AVVA RUS successfully passes an audit by Saudi Arabian FDA bodies for compliance with GMP standards of that region.

• 2018

  AVVA RUS receives European GMP EU certificate; agreements signed with a company in Mongolia for supply of AVVA RUS products.

• 1996

  Alexey Glebovich Egorov begins tenure as General Director (per company leadership listing 1996–2026).

Russian pharmaceutical manufacturer focused on gastroenterology and dermatology, emphasizing original drugs with improved safety profiles and international GMP-certified quality.

• Lactofiltrum 355 mg + 120 mg

  Tablets combining lactulose and hydrolyzed lignin; a unique 'sorbent + prebiotic' combination for gastroenterology and dermatology. Available in 30 and 60 tablet packs. Cleanses the body of toxins, allergens and harmful bacteria; restores microflora.

• Filtrum 400 mg

  Hydrolyzed lignin tablets for gastroenterology. Powerful sorbent action due to millions of pores in each tablet, for the whole family. Available in 10 and 50 tablet packs. Fights various intestinal disorders and poisonings.

• Mikrazim 25,000 IU

  Modern enzyme preparation in capsules containing pancreatin, aiding improved food digestion. Available in 20 and 50 capsule packs. Eliminates symptoms of chronic pancreatitis and dyspeptic symptoms in digestive disorders.

• Mikrazim 10,000 IU

  Modern enzyme preparation in capsules containing pancreatin, for digestive support.

1. 1АВВА РУС – фармацевтическая компанияavva-rus.ru
2. 2История создания компании | АВВА РУСavva-rus.ru
3. 3О фармацевтической компании | АВВА РУСavva-rus.ru
4. 4Контроль качества лекарственных средств | АВВА РУСavva-rus.ru
5. 5JSC AVVA RUS (Russia) – Wikidatawikidata.org